Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression
IgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2458184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583172654628864 |
|---|---|
| author | Ran Zhang Yuyan Tang Xiangru Feng Xiaoxuan Lu Mengyao Zhao Jiayang Jin Xiaoguo Ji Haidong He Liming Zhao |
| author_facet | Ran Zhang Yuyan Tang Xiangru Feng Xiaoxuan Lu Mengyao Zhao Jiayang Jin Xiaoguo Ji Haidong He Liming Zhao |
| author_sort | Ran Zhang |
| collection | DOAJ |
| description | IgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota alteration and the mechanisms by which gut microbiota might trigger IgAN. Furthermore, this study examined the effects of chitooligosaccharides (COS) and COS formulation (COSF) with microbiota-targeting function on enhancing intestinal barrier and renal functions. These results revealed that IgAN led to a reduction in α-diversity and structural alterations in the gut microbiota, characterized by an increase in Shigella sonnei, Streptococcus danieliae, Desulfovibrio fairfieldensis, and a decrease in Bifidobacterium pseudolongum and Clostridium leptum. There was also an imbalance in intestinal B-cell immunity and a decrease in the level of tight junction proteins (ZO-1 and Occludin). Intestinal barrier and mucosal immune-related microbiota (Clostridium leptum, unclassified Lachnospiraceae NK4Al36 group, unclassified Clostridia vadinBB60 group, unclassified Oscillospiraceae, and unclassified Roseburia) were enriched through targeted modulation with COS/COSF, enhancing intestinal ZO-1 expression and reducing APRIL/BAFF overexpression, thereby reducing renal damage in IgAN. In conclusion, this study clarified the kidney-gut crosstalk between gut microbiota and IgAN, providing scientific evidence for developing microbiota-targeted food interventions to improve IgAN outcomes. |
| format | Article |
| id | doaj-art-8472563027974c43af18a4fa3e3a9739 |
| institution | Kabale University |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-8472563027974c43af18a4fa3e3a97392025-01-29T03:57:09ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2458184Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progressionRan Zhang0Yuyan Tang1Xiangru Feng2Xiaoxuan Lu3Mengyao Zhao4Jiayang Jin5Xiaoguo Ji6Haidong He7Liming Zhao8State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaDepartment of Nephrology, Minhang Hospital, Fudan University, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaDepartment of Nephrology, Minhang Hospital, Fudan University, Shanghai, ChinaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, ChinaIgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota alteration and the mechanisms by which gut microbiota might trigger IgAN. Furthermore, this study examined the effects of chitooligosaccharides (COS) and COS formulation (COSF) with microbiota-targeting function on enhancing intestinal barrier and renal functions. These results revealed that IgAN led to a reduction in α-diversity and structural alterations in the gut microbiota, characterized by an increase in Shigella sonnei, Streptococcus danieliae, Desulfovibrio fairfieldensis, and a decrease in Bifidobacterium pseudolongum and Clostridium leptum. There was also an imbalance in intestinal B-cell immunity and a decrease in the level of tight junction proteins (ZO-1 and Occludin). Intestinal barrier and mucosal immune-related microbiota (Clostridium leptum, unclassified Lachnospiraceae NK4Al36 group, unclassified Clostridia vadinBB60 group, unclassified Oscillospiraceae, and unclassified Roseburia) were enriched through targeted modulation with COS/COSF, enhancing intestinal ZO-1 expression and reducing APRIL/BAFF overexpression, thereby reducing renal damage in IgAN. In conclusion, this study clarified the kidney-gut crosstalk between gut microbiota and IgAN, providing scientific evidence for developing microbiota-targeted food interventions to improve IgAN outcomes.https://www.tandfonline.com/doi/10.1080/19490976.2025.2458184IgA nephropathygut microbiotachitooligosaccharideskidney-gut crosstalkhuman microbiota-associated mice |
| spellingShingle | Ran Zhang Yuyan Tang Xiangru Feng Xiaoxuan Lu Mengyao Zhao Jiayang Jin Xiaoguo Ji Haidong He Liming Zhao Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression Gut Microbes IgA nephropathy gut microbiota chitooligosaccharides kidney-gut crosstalk human microbiota-associated mice |
| title | Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression |
| title_full | Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression |
| title_fullStr | Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression |
| title_full_unstemmed | Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression |
| title_short | Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression |
| title_sort | targeted modulation of intestinal barrier and mucosal immune related microbiota attenuates iga nephropathy progression |
| topic | IgA nephropathy gut microbiota chitooligosaccharides kidney-gut crosstalk human microbiota-associated mice |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2458184 |
| work_keys_str_mv | AT ranzhang targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT yuyantang targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT xiangrufeng targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT xiaoxuanlu targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT mengyaozhao targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT jiayangjin targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT xiaoguoji targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT haidonghe targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression AT limingzhao targetedmodulationofintestinalbarrierandmucosalimmunerelatedmicrobiotaattenuatesiganephropathyprogression |